Denali Therapeutics (DNLI) Profit After Tax (2017 - 2026)

Denali Therapeutics (DNLI) has reported Profit After Tax for 10 consecutive years, with -$129.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 2.38% year-over-year to -$129.8 million; the TTM figure through Mar 2026 stood at -$509.4 million (down 12.22% YoY), while the FY2025 annual figure was -$512.5 million, down 21.63% from the prior year.
• Profit After Tax declined to -$129.8 million in Q1 2026 per DNLI's latest filing, from -$128.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $183.4 million in Q2 2023 and bottomed at -$133.0 million in Q1 2025.
• Historically, Profit After Tax has averaged -$90.0 million across 5 years, with a median of -$107.2 million in 2024.
• Annual changes were most pronounced in 2023 — Profit After Tax surged 396.65% — and 2024, when it sank 154.74%.
• Denali Therapeutics' Profit After Tax stood at -$89.3 million in 2022, then retreated by 25.32% to -$111.9 million in 2023, then retreated by 1.28% to -$113.4 million in 2024, then retreated by 13.38% to -$128.5 million in 2025, then fell by 0.98% to -$129.8 million in 2026.
• Business Quant data shows DNLI's Profit After Tax at -$129.8 million in Q1 2026, -$128.5 million in Q4 2025, and -$126.9 million in Q3 2025.